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The natural antibiotic teixobactin kills pathogenic bacteria without detectable resistance. The
difficult synthesis and unfavourable solubility of teixobactin require modifications, yet
insufficient knowledge on its binding mode impedes the hunt for superior analogues. Thus far,
teixobactins are assumed to kill bacteria by binding to cognate cell wall precursors (Lipid II
and III). Here we present the binding mode of teixobactins in cellular membranes using solid-
state NMR, microscopy, and affinity assays. We solve the structure of the complex formed by
an improved teixobactin-analogue and Lipid II and reveal how teixobactins recognize a broad
spectrum of targets. Unexpectedly, we find that teixobactins only weakly bind to Lipid II in
cellular membranes, implying the direct interaction with cell wall precursors is not the sole
killing mechanism. Our data suggest an additional mechanism affords the excellent activity of
teixobactins, which can block the cell wall biosynthesis by capturing precursors in massive
clusters on membranes.
https://doi.org/10.1038/s41467-020-16600-2 OPEN
1 NMR Spectroscopy, Bijvoet Centre for Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Padualaan 8, 3584 CH
Utrecht, The Netherlands. 2Membrane Biochemistry and Biophysics, Bijvoet Centre for Biomolecular Research, Department of Chemistry, Utrecht University,
Padualaan 8, 3584 CH Utrecht, The Netherlands. 3 School of Pharmacy, JBL Building, University of Lincoln, Beevor St, Lincoln, UK. 4 Department of Chemistry
‘Ugo Schiff’, University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino (FI), Italy. 5 Section Molecular Host Defence, Division Infectious Diseases &
Immunology, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands.
6Present address: Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool,
Sherrington Building, L69 3GA Liverpool, UK. 7Present address: Department of Chemistry, The Robert Robinson Laboratories, University of Liverpool, L69 3BX
Liverpool, UK. 8These authors contributed equally: Rhythm Shukla, João Medeiros-Silva. ✉email: M.H.weingarth@uu.nl
NATURE COMMUNICATIONS |         (2020) 11:2848 | https://doi.org/10.1038/s41467-020-16600-2 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Teixobactin, the first of a new class of antibiotics, kills abroad spectrum of clinically relevant multi-drug resistantpathogens, such as methicillin-resistant Staphylococcus
aureus and Mycobacterium tuberculosis with excellent activity1.
Teixobactin is a natural undecapeptide from Eleftheria terrae that
comprises several uncommon residues including D-amino-acids
and L-allo-enduracididine, with the last four residues forming a
ring motif. Given that it inhibits bacterial cell wall synthesis by
targeting conserved non-proteinogenic molecules (Lipid II and
III) in the plasma-membrane (Fig. 1a)1, development of resis-
tance against teixobactin is difficult2–4.
Notwithstanding the high therapeutic potential of teixobactin,
progress towards its realization requires access to a large library of
analogues due to high attrition rates in drug development5 and
shortcomings, such as difficult and prohibitively expensive
synthesis or insufficient solubility. Several research groups have
addressed these shortcomings6–10. However, due to a funda-
mental lack of knowledge on the binding mode of teixobactin, the
search for improved analogues has been largely based on coin-
cidental discoveries. Structural insights on its binding mode are
scarce11,12 and reported data were collected in water or micelles
using truncated Lipid II mimics, i.e., in non-physiological con-
ditions. The lack of data in natural membrane settings is espe-
cially problematic because the binding mode and activity of Lipid
II-binding antibiotics can be highly sensitive to the cellular
environment13.
Here we use solid-state NMR (ssNMR) spectroscopy, fluorescence
microscopy, and affinity studies to determine at atomic resolution
the native mode of action of the improved analogues14 [R4L10]-
teixobactin and [L10]-teixobactin (Fig. 1b and Supplementary Fig. 1)
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Fig. 1 Teixobactins capture their target Lipid II in large clusters on the membrane. a Teixobactins target cognate cell wall-precursors Lipid II and Lipid III
in the bacterial plasma-membrane. b Chemical structure of [R4L10]-teixobactin in which D-Gln4 and L-allo-enduracididine10 of natural teixobactin are
replaced by D-Arg4 and L-Leu10, respectively. 13C,15N-labelled residues are coloured in blue. c 2D 15N1H ssNMR spectrum of Lipid II-bound [R4L10]-
teixobactin showing all six 13C,15N-labelled residues. d β-structuring of the N-terminus (Ile2–Ile6) of Lipid II-bound [R4L10]-teixobactin shown by Cαβ
secondary chemical shifts (SCS)15. Source data are provided as a Source Data file. e Contacts observed in f between Ile2–Ser7 relate to intermolecular
magnetization transfer between antiparallel β-strands. Distances are Cα–Cα spacings. f Overlay of 2D 13C13C PARISxy48 spectra of Lipid II-bound [R4L10]-
teixobactin measured with 50 (blue) and 600ms (grey) magnetization transfer time. Intermolecular peptide–peptide contacts in red, sequential contacts in
blue. All NMR spectra were acquired at 950MHz. g Lipid II segregation caused by teixobactins visualized by fluorescence microscopy: GUVs doped with
NBD-labelled Lipid II before (left) and after (right) treatment with [R4L10]-teixobactin.
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in bacterial cellular membranes. We disclose that teixobactins trap
Lipid II in μm-sized clusters on membrane surfaces as an alternative
killing mechanism. We solve the structure of the complex
between [R4L10]-teixobactin and Lipid II in these clusters, which
provides detailed insights into the pharmacophore and explains how
teixobactins mitigate antimicrobial resistance development. Unex-
pectedly, we find that the binding affinity of teixobactins for Lipid II
is strongly attenuated if membranes are anionic, which is commonly
the case for bacterial plasma-membranes. Together, our data raise
astounding questions on the mode of action of teixobactins, which is
more complex than previously thought.
Results
Teixobactins form large clusters on membrane surfaces. We
made [R4L10]-teixobactin amenable to ssNMR by synthetically14
13C,15N-isotope labelling six residues (Ile2, Ser3, Ile6, Ser7, Ala9,
Leu10) that cover the whole molecule. Co-assembly of [R4L10]-
teixobactin and Lipid II in DOPC membranes resulted in well-
resolved ssNMR correlation spectra that demonstrate the for-
mation of a well-defined complex (Fig. 1c and Supplementary
Fig. 2). We assigned the chemical shifts of [R4L10]-teixobactin
using 2D 13C13C and 3D CαNH and CONH experiments. The
chemical shifts report on the secondary structure15 and show that
the N-terminus of Lipid II-bound [R4L10]-teixobactin adopts a
β-strand conformation (Fig. 1d), which matches with its high
rigidity (Supplementary Fig. 2). β-structuring was also observed
in a teixobactin–sulfate complex in water11 and in micelles with a
truncated Lipid II variant12. This implies that β-structuring is a
natural part of the binding mode that neither requires a mem-
brane nor a complete receptor.
We hypothesized that β-structuring is caused by the oligomer-
ization of Lipid II-bound teixobactins, in line with previously
observed peptide aggregation behaviour in micelles12. We first
examined the atomic-scale intermolecular arrangement of
[R4L10]-teixobactins by a 2D 13C13C ssNMR spectrum with a
long magnetization transfer time that probes distances between
13C nuclei with a threshold of ~8 Å. We observed Cα–Cα contacts
between residues Ile2–Ser7, Ile2–Ile6, and Ser3–Ser7 (Fig. 1e, f)
that must stem from intermolecular magnetization transfer
between antiparallel β-strands, given that the Cαi–Cαi+5 distance
within the same β-strand is 15–18 Å. We confirmed the
oligomerization with pyrene excimer fluorescence, which demon-
strated that Lipid II molecules are within 1–2 nm of each other in
the bound state (Supplementary Fig. 3)16. The oligomerization of
Lipid II occurs virtually immediately after addition of [R4L10]-
teixobactin, which suggests that antibiotic molecules need to
come together to efficiently bind Lipid II, in agreement with the
loss of activity of N-terminally truncated teixobactins that cannot
oligomerise17.
We used fluorescence microscopy and 7-nitrobenz-2-oxa-1,3-
diazol-4-yl-(NBD)-tagged Lipid II in giant unilamellar vesicles
(GUVs) to visualize the macroscopic state of bound teixobactins
(Fig. 1g and Supplementary Fig. 4)18. To our surprise, we
observed that Lipid II segregated into μm-sized clusters upon
addition of [R4L10]-teixobactin, while it was initially homo-
geneously distributed over the GUV surface. We validated with
[L10]-teixobactin, which is a close analogue of the natural
antibiotic1, that the segregation of Lipid II into clusters is a
common property of teixobactins (Supplementary Fig. 4). While
oligomerization is fast, cluster formation is a slower subordinate
process that occurs on a timescale of about 2–4 h, which is the
same timescale on which bacterial killing by teixobactins is
observed1,9,19. Together, our data suggest that the capturing in
large clusters makes Lipid II molecules unavailable for the
peptidoglycan biosynthesis, which is an alternative killing
mechanism similar to lantibiotics18.
Complex interface and topology. Teixobactins target Lipid II, a
complex lipid with a pyrophosphate (PPi) and a headgroup com-
posed of two sugars (MurNAc and GlcNAc) and a pentapeptide
(Fig. 2c). We used ssNMR to determine the [R4L10]-
teixobactin–Lipid II complex interface and topology in membranes.
We first examined how the antibiotic targets PPi. 31P ssNMR
data in membranes show stark changes of the Lipid II PPi signals
upon binding of [R4L10]-teixobactin, suggesting a direct inter-
action (Fig. 2a). Indeed, 2D 1H31P ssNMR data established that
backbone amino protons of [R4L10]-teixobactin directly coordi-
nate the pyrophosphate (Fig. 2b). The interfacial correlations
match with the amino protons of Ala9 and Leu10, showing that
the ring motif of [R4L10]-teixobactin coordinates PPi. Con-
versely, we observed no correlation for Ser7, which means that
Ser7 and the β-structured N-terminus are not part of the PPi-
binding interface.
We next show how the Lipid II sugar-pentapeptide headgroup
participates in the complex. For this, we developed an approach
to 13C,15N-label Lipid II, which has high potential to characterize
the binding modes of other promising antibiotics18,20,21. We used
2D 13C13C spectra to pinpoint the interface between 13C,15N-
[R4L10]-teixobactin and 13C,15N-Lipid II (Fig. 2c, d and
Supplementary Fig. 5). While we observed intense signals for
the Lipid II sugars, those of the pentapeptide were faint or absent.
Since we used dipolar-based ssNMR experiments in which only
rigid residues give signals, our data imply that the pentapeptide is
mobile and hence likely not part of the interface. This was
confirmed with a scalar-based ssNMR experiment that enables
detection of mobile residues, showing the missing pentapeptide
signals (Supplementary Fig. 6). For the sugars, we obtained many
interfacial contacts that all related to Ala9 and Leu10, confirming
the interaction of the ring motif of [R4L10]-teixobactin with Lipid
II (Fig. 2c). MurNAc, which is covalently attached to Lipid II PPi,
shows a large number of contacts, implying its direct presence at
the interface (Fig. 2e), whereas we obtained only one low-
intensity unambiguous correlation with GlcNAc, suggesting that
the second sugar is only remotely involved in the interface.
We determined the membrane-topology of Lipid II-bound
[R4L10]-teixobactin using a mobility-edited ssNMR experiment22
in which magnetization from mobile water or lipids is transferred
to the rigid antibiotic (Supplementary Fig. 7). We found that
[R4L10]-teixobactin localizes at the water–membrane interface
with the non-polar residues Ile2 and Ile6 partitioned in the
bilayer. Together, our data provide a detailed description of the
complex in membranes (Fig. 2f).
High-resolution structure of the complex. We next calculated
using HADDOCK23 a complex of four [R4L10]-teixobactin and
Lipid II molecules as minimal binding motif. The structure cal-
culations were based on interfacial distance restraints between
[R4L10]-teixobactin and Lipid II, distance restraints between
[R4L10]-teixobactin monomers, and dihedral angle restraints. We
note that our structural insights are limited by the lack of isotope-
labels for 5 out of 11 residues in [R4L10]-teixobactin.
The obtained structures superimposed well (1.77 ± 0.49 Å
RMSD for [R4L10]-teixobactin) (Fig. 3a and Supplementary
Fig. 8) and reveal antiparallel [R4L10]-teixobactin fibre-like β-
sheets. Pairs of β-strands are shifted with respect to each other,
which leaves the ring motif free to bind Lipid II. The complex
shows that the critical sequence of D- and L-amino acids in
teixobactins10 enables separation of hydrophilic and hydrophobic
residues (Fig. 3c), i.e., sidechains of sequential pairs of D- and
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L-residues (e.g., D-N-Me-Phe1 and L-Ile2/D-allo-Ile5 and L-Ile6)
are located on the same side of the β-sheet. The long hydrophobic
sidechains of N-Me-Phe1, Ile2, Ile5, and Ile6 align and act as
membrane-anchors (Fig. 3d), in agreement with computational
data24, explaining why substitutions by polar8,25 or short26
sidechains or inversion from D to L configuration10 lead to
complete loss of activity. The only long hydrophobic sidechain
that did not point towards the membrane-side is Ile11
(Supplementary Fig. 9), whose substitution by alanine is
tolerated26. The hydrophilic Ser3, Arg4, and Ser7 are water-
exposed and form hydrogen bonds that, enabled by the long
Arg4 sidechain, connect three [R4L10]-teixobactin molecules
(Supplementary Fig. 9).
The ring amino protons (Thr8-Ile11) and the cationic N-
terminus of a neighbouring teixobactin molecule coordinate the
pyrophosphate of Lipid II. This explains why the presence of a
positively charged N-terminus is critical for the activity27 and
shows that dimer formation of teixobactins is required for
efficient Lipid II binding (Fig. 3b). The MurNAc sugar also
directly contacts the ring motif, while GlcNAc is distal from the
drug and the mobile pentapeptide adopts random orientations.
Non-polar groups of MurNAc face the hydrophobic
Leu10 sidechain, which possibly contributes to the good activity
of teixobactins with branched-chain residues (Leu, Ile, Val) at
position 1014. Diverse hydrophobic and cationic residues are
however tolerated at positions 9 and 10 of the ring motif10,17,26,
which shows that interactions with MurNAc and GlcNAc are of
low specificity. Analogously, our ssNMR data, in line with MD
simulations24, exclude specific interactions with the pentapeptide.
We validated that teixobactins are able to bind a broad
spectrum of cognate cell wall precursors1 by comparing (i) Lys-
Lipid II, (ii) mDAP-Lipid II, and (iii) Lys-Lipid I. While Lipid I
lacks the GlcNAc sugar, mDAP-Lipid II has a different
pentapeptide. While Gram-positive bacteria have a cationic
Lysine (Lys-Lipid II) in the pentapeptide, it is replaced by a
zwitterionic meso‐diaminopimelic acid (mDAP) in Gram-
negative (mDAP-Lipid II) (Fig. 2c)2,3. As expected, [R4L10]-
teixobactin bound to Lys-Lipid II or mDAP-Lipid II gave the
same ssNMR spectra, in line with high mobility of the
pentapeptide and the absence of interfacial contacts with the
pentapeptide. [R4L10]-teixobactin was also able to bind Lys-Lipid
I and exhibited clear signal changes in the ring motif (Fig. 4a and
Supplementary Fig. 10), showing that GlcNAc modulates,
presumably allosterically, drug binding.
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Fig. 2 Binding to the pyrophosphate and first sugar of Lipid II is dominant. a 1D 31P spectra of Lipid II in liposomes in the presence (pink) and absence
(gray) of [R4L10]-teixobactin. Orange asterisks mark PPi signals; bulk lipids come around 0 ppm. b 2D 1H31P spectrum of the complex. Dashed lines
indicate chemical shifts of the amino protons of Ser7, Ala9, and Leu10. c Chemical model of Lipid II. d 2D 13C13C PARISxy48 spectra of the 13C,15N-labelled
complex measured using 50 (cyan) and 600ms (yellow) magnetization transfer time. Contacts within and between [R4L10]-teixobactin molecules
labelled in black, intramolecular Lipid II contacts in blue, interfacial contacts in red. See Supplementary Fig. 5 for the full spectrum. e Sum of interfacial
contacts between [R4L10]-teixobactin and the sugars MurNAc (magenta) and GlcNAc (green); ambiguous contacts in gray. Source data are provided as a
Source Data file. f Illustration of interface and topology of the complex. [R4L10]-teixobactin resides at the water–lipid interface with Ile2 and Ile6
partitioning into the membrane. The ring motif coordinates PPi. MurNAc (M, magenta) and, to a minor extent, GlcNAc (G, green) also interact with the
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In summary, a picture of a balanced binding mode emerges in
which teixobactins use the conserved pyrophosphate as firm,
specific anchor, whereas the interaction with the sugar-pentapeptide
headgroup is more loosely defined28,29. This behaviour enables
teixobactins to recognize different cognate cell-wall building blocks
and wall teichoic acids precursors, such as Lipid I, Lipid II, Lipid III,
and undecaprenyl pyrophosphate that all have the PPi moiety in
common but feature different headgroups1. The capacity to
recognize several conserved precursor molecules both maximizes
the number of targets and decreases the likelihood of the
development of efficient resistance mechanisms against teixobac-
tins. Taken together, a molecular rationale emerges for the broad
activity spectrum of teixobactins and for their ability to bind, unlike
vancomycin, Lipid II versions with different pentapeptides30.
Cellular conditions change the binding mode. Eventually, we
examined the impact of the membrane composition that can be
critical for the native binding mode and is unknown for teix-
obactins. We probed the impact of the membrane charge with
comparative ssNMR measurements in neutral DOPC and anionic
DOPG liposomes (Fig. 4a, b). In anionic membranes, we observed
widespread signal changes for residues Ile2, Ser7, Ala9, and Leu10,
showing impact on both the N- and C-termini which teixobactins
use to coordinate Lipid II. Unexpectedly, ssNMR signal intensity
dropped by a factor of six in anionic membranes (Supplementary
Fig. 11). Since ssNMR sensitivity may inversely correlate with
molecular mobility, we hypothesized that the dynamics of the
complex was augmented in anionic membranes. Indeed, ssNMR
relaxation data confirmed a stark increase in mobility of Lipid II-
bound [R4L10]-teixobactin with increasing anionic membrane
charge (Fig. 4c). This mobility increase is of global nature and
similar for the entire peptide and the well-resolved residue Ser7. We
validated with a second analogue, [L10]-teixobactin, that reduced
ssNMR sensitivity and enhanced dynamics are common in anionic
membranes (Supplementary Fig. 11).
The drop in sensitivity and the increase in dynamics likely
point to a decreased binding affinity to Lipid II in anionic
membranes. We compared binding affinities between [R4L10]-
teixobactin and Lipid II in neutral and anionic membranes with
isothermal titration calorimetry (ITC)31. We found a much
weaker binding affinity in membranes containing anionic lipids,
with an equilibrium dissociation constant Kd that increased from
0.17 μM in neutral membranes to 21.9 μM in membranes
containing 25% (mol/mol) of anionic lipids (Fig. 4d, e).
We hypothesized that the stark impact of the membrane
composition should modulate the cellular binding mode of
teixobactins, which is eventually decisive for drug design.
SSNMR32–35 enables high-resolution drug–receptor studies in
crowded cellular conditions13, but requires highly sensitive
methods such as 1H-detection13,36 and dynamic nuclear polar-
ization (DNP)33,35,37,38 due to the minute native Lipid II
concentration39, which is maximally 0.5–1 % of the membrane
lipids40. Here, we investigated the [R4L10]-teixobactin–Lipid II
complex directly in natural membranes isolated from the Gram-
positive bacterium M. flavus. We first show that the oligomeriza-
tion of teixobactins and the complex structure are conserved in
natural membranes, which is visible from the good match of
DNP-ssNMR 2D 13C13C spectra in cellular and in vitro (DOPC)
conditions (Supplementary Fig. 12). Next, we sought to reveal an
impact of the cellular environment with a well-resolved 2D NH
spectrum (Fig. 4a, right panel). Intriguingly, the cellular 2D NH
dc
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spectrum of bound [R4L10]-teixobactin strongly resembled the
one in anionic membranes, in line with a high content of anionic
lipids (up to 90%) in Micrococcal membranes41. Since the binding
affinity to Lipid II is much lower in anionic membranes, our data
imply that teixobactins bind Lipid II with considerably reduced
affinity under cellular conditions given that bacterial plasma-
membranes are negatively charged41. A molecular rationale for
the observed effect could be the interaction of anionic lipids with
the cationic N-terminal charge and the ring motif.
Discussion
In this study, we have presented an in-depth analysis of the
binding mode of teixobactins in cellular membranes. We have
presented a high-resolution structure of a teixobactin-analogue in
complex with Lipid II in lipid membranes (Fig. 3). The structure
provides a wealth of information on the pharmacophore and
demonstrates that teixobactins balance specific and fuzzy binding
to recognize a maximal number of targets and to minimize the
likelihood of resistance development. Furthermore, our structure
explains the critical sequence of D- and L-amino acids that enables
a clear-cut separation of hydrophilic and hydrophobic sidechains
and thereby also provides a molecular rationale why certain
positions do not tolerate substitutions of hydrophobic residues by
hydrophilic residues and vice versa8,10,25,26,42,43.
Besides the structure, our study presents two other major
findings, which are that teixobactins form μm-sized clusters on
membrane surfaces and that their binding affinity to Lipid II is
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Fig. 4 Teixobactins have low affinity for Lipid II in anionic membranes. a 2D 15N1H ssNMR spectra of [R4L10]-teixobactin bound to Lys-Lipid II in DOPC
(cyan), mDAP-Lipid II in DOPC (violet), Lys-Lipid I in DOPC (green), Lys-Lipid II in DOPG (pink), and in cellular Micrococcus flavus membranes (orange).
The cellular spectrum was measured with 7.5 nmol (<10 μg) of drug. b Illustration of spectral differences shown in a. HN CSPs >0.15 ppm are shown in
colours, isotope-labelled residues with smaller CSPs in gray. c ssNMR microsecond dynamics of bound [R4L10]-teixobactin for different membrane and
receptor types. The error bars show the standard error of the fit. Source data are provided as a Source Data file. d Representative isothermal titration
calorimetry (ITC) data of [R4L10]-teixobactin and Lys-Lipid II in neutral DOPC and e anionic membranes, composed of a 1:3 (mol/mol) DOPG:DOPC
mixture. ITC measurements were performed in triplicate for each system.
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markedly reduced in anionic membranes. The impact of mem-
brane lipids on teixobactins was previously not considered. The
modest affinity for Lipid II in membranes that contain high
amounts of anionic lipids is particularly surprising because most
bacterial membranes are strongly anionic and teixobactins show
high activity against a broad bacterial spectrum1,14. The direct
binding of cell wall precursors is hence unlikely solely responsible
for bacterial killing by teixobactins. Our data suggest that the
subsequent slower formation of μm-sized clusters, that separates
precursors from the cell wall biosynthesis and occurs on
the timescale on which teixobactins kill bacteria, is an additional
mode of action, and potentially even the more relevant one in
physiological conditions. The relevance of cluster formation for
activity is also congruent with studies of fluorescent teixobactins
that showed pronounced staining of cell wall synthesis sites in
Gram-positive bacteria44. Cell wall precursors presumably get
effectively entangled in the massive clusters despite a relatively
weak binding affinity to teixobactins in anionic cellular condi-
tions. Indeed, we validated with fluorescence microscopy that
teixobactins are able to efficiently capture Lipid II in clusters in
anionic membranes (Supplementary Fig. 13). While cluster for-
mation was previously only observed for lantibiotics18, it is hence
a more common mode of action of antibiotics that target cell wall
precursors.
Future studies on how membrane lipids and cluster formation
modulate the activity of teixobactins are urgently required to
understand the mode of action of teixobactins. Our data also
provide compelling evidence that such studies require physiolo-
gically relevant media and, ideally, cellular conditions13. In this
regard, concerted optimization of cluster formation and of the
binding affinity to different cell wall building blocks in relevant
membrane conditions may lead to further improvements in the
design of teixobactins. These insights may critically advance our
capacity to develop potent antibiotics against multi-drug resistant
bacteria.
Methods
Materials. Phospholipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (C18:1,
DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (C18:1, DOPG) were pur-
chased from Avanti Polar Lipids, Inc.
Isothermal titration calorimetry. Preparation of liposomes: For ITC measure-
ments large unilamellar vesicles (LUVs) containing Lys-Lipid II were prepared by
incorporating 2% (mol/mol) of Lys-Lipid II in DOPC from the stock solution. The
lipids were dried by nitrogen stream and hydrated with 10 mM HEPES, 150 mM
NaCl, pH 7.5 buffer to a lipid-phosphate concentration of ~20 mM. LUVs were
obtained after 10 rounds of extrusion through 200 nm membrane filters (Whatman
Nuclepore, Track-Etch Membranes). The liposomes were dialysed to citrate
phosphate buffer (100 mM NaCl, 50 mM citric acid, 100 mM Na2HPO4, pH ~6).
Anionic LUVs were prepared by mixing 25% (mol/mol) DOPG and 75% (mol/
mol) DOPC and then incorporating 2% (mol/mol) Lys-Lipid II. All other steps
were the same as for zwitterionic LUVs.
ITC was performed with the Low Volume NanoITC (Waters LLC, New Castle,
DE, USA) to determine interaction between LUVs and [R4L10]-teixobactin.
[R4L10]-teixobactin was diluted in a citrate phosphate buffer (100 mM NaCl,
50 mM citric acid, 100 mM Na2HPO4, pH ~6) to a final concentration of 65 μM.
Samples were degassed before use. The chamber was filled with 164 μL of [R4L10]-
teixobactin, and the LUVs were titrated into the chamber at a rate of 1.96 μL/300 s
with a stirring rate of 300 rpm. Experiments were performed at 37 °C and analysed
using the Nano Analyse Software (Waters LLC). All experiments were performed
in triplicate for each system. Control experiments were performed with Lipid II-
free LUVs.
Fluorescence microscopy. GUVs were prepared using the electroformation
method. The GUV cell is a self-assembled system which consists of a 5 mm-thick
Teflon plate which is aligned with two titanium electrodes in a closed Teflon
chamber. 1.5 μL of 0.5 mM DOPC doped with NBD-labelled Lipid II (0.1 mol%)
were brushed on the electrodes. Next, the chamber was filled with 350 μL 0.1 M
sucrose solution; the electrodes dipped in and then connected to a power supply
which generated a sine wave of voltage 2.5 V at a frequency of 10 Hz for 90 min.
Each microscopy slide (μ-slide 8 well, Ibidi) was covered with 350 μL BSA solution
(1 mg/mL). To detach the GUVs from the electrodes the power supply was changed
to square wave of voltage 2 V at a frequency of 2 Hz for 15 min. The slides were
immersed in 300 μL 0.1 mM glucose solution to which 80 μL of GUVs were added.
These were incubated for 4 h with 1 μM [R4L10]-teixobactin and observed by
confocal microscopy. Anionic GUVs were prepared using a homemade electro-
formation setup with ITO coverslips (18 × 18 mm, 15–30Ω, SPI supplies). On both
slips, 3 μL of a chloroform–methanol (1:1, vol/vol) solution containing 1 mM of a
3:1 mixture of DOPC:DOPG (mol/mol) and 0.1 mol% NBD-labelled Lipid II was
deposited and dried in a vacuum desiccator. With these slips, the electroformation
chamber was assembled and filled with 0.1 M sucrose solution. The GUV cell was
connected to the power supply and an alternating current applied (1 V, 10 Hz).
GUV formation was carried out overnight. The GUVs were then incubated with
1 μM [L10]-teixobactin for 4 h in a 0.1 M glucose solution.
Microscopy: GUVs were imaged using Zeiss LSM 880 with ×63/1.2NA glycerol
objective lens. The NBD label appeared green upon excitation by the 488 nm laser.
The emission range for detection was 530–545 nm (λem peak= 539 nm). The
brightfield images were used for detection and location of the GUVs without a
fluorescent signal and also as a control to observe their shape. FIJI software was
used for the image analysis45.
Fluorescence spectroscopy. The oligomerisation of fluorescent pyrene-labelled
Lipid II was observed upon binding of [R4L10]-teixobactin. DOPC LUVs con-
taining 0.5 (mol%) of pyrene-labelled Lipid II in buffer (10 mM Tris–Cl, 100 mM
NaCl, pH 8.0) were prepared as described above. All fluorescence experiments were
performed with a Cary Eclipse (FL0904M005) fluorometer46. All samples (1.0 mL)
were continuously stirred in a 10 × 4-mm quartz cuvette and kept at 20 °C.
[R4L10]-teixobactin was titrated to the LUVs. Pyrene fluorescence was followed
with spectral recordings between 360 and 550 nm (λex 350 nm, bandwidth 5 nm).
The emission at 380 and 495 nm was recorded and averaged over 50 s, to obtain the
values for the monomer and excimer intensity, respectively, to determine the
excimer over monomer ratio for all conditions.
Solid-state NMR spectroscopy. 1D, 2D, and 3D 1H-detected experiments were
performed at 60 kHz MAS frequency using magnetic fields of 16.4, 18.8, and 22.2 T
(700, 800, and 950MHz 1H-frequency) at temperatures of 305 K. All 1H-detected
experiments were dipolar-based. PISSARRO low-power decoupling47 was used
during detection periods. 2D 13C13C spin diffusion experiments were performed
with PARISxy48 recoupling at 950MHz and 15.5, 17, or 18 kHz MAS frequency at
270 K temperature using mixing times of 25–1000 ms. SPINAL6449 was used in
detection periods. The 2D scalar 13C13C TOBSY50 experiment was acquired at
950MHz with 8 kHz MAS at 295 K temperature with 6 ms 13C–13C magnetization
transfer time. Chemical shift assignments were performed using standard 1H-
detected 3D CANH and CONH experiments36,51 in combination with 2D 13C13C
PARISxy48 experiments with different magnetization transfer times (see Supple-
mentary Tables 1 and 2). DNP-enhanced 2D 13C13C spin diffusion (20 ms mixing
time) ssNMR experiments52 were carried out using a 263 GHz microwave fre-
quency, 400MHz 1H frequency setup (Bruker Biospin) at 100 K temperature and
8.5 kHz MAS.
Topological studies: The mobility-edited 2D 1H(1H)13C experiment22 was
performed at 700MHz with 16.5 kHz MAS at 300 K temperature using a T2
relaxation filter of 2.5 ms. After dephasing of the rigid signals, magnetization from
mobile lipid and water molecules was transferred to the rigid antibiotic with 5 ms
1H–1H mixing, and subsequently transferred to 13C nuclei of [R4L10]-teixobactin
with a short (200 μs) cross-polarization step.
Structural studies: To probe intermolecular contacts between 13C,15N-
labelled [R4L10]-teixobactin molecules bound to unlabelled (12C,14N) Lipid II, we
ran 2D 13C13C PARIS experiments with magnetization transfer times of 50, 300,
600, and 1000 ms at 950MHz and 15.5 kHz MAS. To probe interfacial contacts
between 13C,15N-labelled [R4L10]-teixobactin and 13C,15N-labelled Lipid II, we
ran 2D 13C13C PARIS experiments with magnetization transfer times of 25, 50,
600, and 1000 ms at 950MHz and 18 kHz MAS. 1D 31P CP experiments were
acquired at 500MHz with 12 kHz MAS. The 2D 1H31P experiment was acquired at
800MHz magnetic field and 60 kHz MAS using 1.75 ms CP transfer from 1H to
31P.
Studies of the impact of membrane and receptor composition: 2D NH
experiments were conducted with different numbers of scans due to strongly
decreased spectral sensitivity with increasing anionic membrane charge.
Relaxation studies: 1H-detected 15N T1rho relaxation experiments were carried
out at 950 and 700MHz magnetic field, respectively, using 60 kHz MAS51. The 15N
transverse magnetization decay was probed with a 15N spinlock field of 17.5 kHz.
For the bulk, we measured the intensity of the most intense signal at ~8.80 1H ppm.
T1rho trajectories were fit to single exponentials.
NMR structure calculation. Parameterization of [R4L10]-teixobactin: An initial
linear [R4L10]-teixobactin topology was generated in CNS 1.253. D-amino
acids were generated by inverting relevant dihedral and improper torsion angles.
D-Me-Phe N-methyl group parameters were based on monomethyl lysine
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(as accommodated by HADDOCK). The rings were defined by manually removing
Thr8 hydroxyl proton and Ile11 carboxyl –OH from the topology, and introducing
the relevant bond lengths, bond angles, dihedral angles, and improper torsion
angles in the topology. Ester bond geometric parameters were based on the crystal
structure of a teixobactin analogue (PDB 6E00)11; partial charges were based on
protonated glutamic acid sidechain (as defined in the OPLS54 force field used in
HADDOCK). A monomeric [R4L10]-teixobactin starting model for HADDOCK
structure calculation was then generated in CNS55, using only dihedral angle
restraints for residues Ile2-Ser7 initially obtained from an X-ray structure11 and
validated by our chemical shift analysis (see Supplementary Information).
Parameters for Lipid II were taken from ref. 56.
NMR restraints: NMR structure calculations were performed with HADDOCK
version 2.423. SSNMR restraints are described in detail in the Supplementary
Information. In total, we used 23 intermolecular [R4L10]-teixobactin–[R4L10]-
teixobactin NMR distance restraints to define the fibre-like β-sheet formed by
oligomerised teixobactins; 22 intermolecular [R4L10]-teixobactin–Lipid II NMR
distance restraints were used to define the antibiotic–receptor interface. The
structure of [R4L10]-teixobactin was further defined by 12 dihedral restraints and 7
intramolecular NMR distance restraints. The head-group structure of Lipid II was
further defined by 21 NMR distance restraints. See Supplementary Table 3 for a
summary of the restraints.
Structure calculation protocol: HADDOCK version 2.423 was used for the
structure calculations. An eight-body docking (4 Lipid II and 4 [R4L10]-teixobactin
molecules) was performed using the distance and dihedral restraints described
above. 7000 models were generated in the rigid body docking stage of HADDOCK,
of which the best scoring 500 were subjected to the flexible refinement protocol of
HADDOCK. The resulting models were finally refined in explicit solvent. Default
HADDOCK settings were used except for doubling the weighting of the distance
restraints during all stages of the structure calculation. The final models were
further filtered based on the topological requirements (i.e., the hydrophobic tails of
all four Lipid II molecules must point in the same direction as the membrane-
anchoring residues Ile2, Ile5, and Ile6). This resulted in a final ensemble of
26 structures.
Analysis of calculated structures: Structural and violation statistics of the final
26 structures are discussed in detail in the Supporting Information. The average
backbone RMSD (from the average structure) of the 26 [R4L10]-teixobactin
molecules in the complex was 1.77 ± 0.49 Å.
Sample preparations. Lipid II was synthesized based on enzymatic lipid
reconstitution using the Lipid II precursors UDP-GlcNAc, UDP-MurNAc-
pentapeptide, and polyisoprenolphosphate as substrates16. Lysine-form UDP-
MurNAc-pentapeptide was extracted from Staphylococcus simulans 22, whereas
the mDAP-form was obtained from Bacillus subtills 168. 13C,15N-labelled UDP-
GlcNAc and UDP-MurNAc-pentapeptide (lysine form) were extracted from
S. simulans 22 grown in [13C,15N]-labelled rich medium (Silantes) and supple-
mented with [U-13C]-D-glucose and [15N]-NH4Cl (Supplementary Fig. 14a).
Polyisoprenophosphate was synthesized via phosphorylation of polyisoprenol
obtained from Laurus nobilis57. The head-group precursors were extracted from
bacteria and polyisoprenol was extracted from leaves as described58,59. After
synthesis, Lipid II was extracted with 2:1 BuOH:(Pyr/Acetate, 6 M) and purified
with a DEAE cellulose resin (acetate-form, BiopHoretics) using a salt gradient
(Supplementary Fig. 14b, c). Fractions containing pure Lipid II were pooled,
dried, and dissolved in 2:1 chloroform/methanol. Lipid II concentration was
estimated through an inorganic phosphate determination60. The labelled Lipid II
yield was ~1.0 μmol/L. Lipid I was produced in the same manner, but without
adding UDP-GlcNAc.
Lipid I or II-doped multi-laminar vesicle preparations: DOPC or DOPG lipids
were mixed with Lipid I or II in 1:1 MeOH:CHCl3 at the final Lipid I or II molar
ratio (0–4 mol%/mol). The mixtures were dried and the lipid films were hydrated
by vortexing with 2 mL of a teixobactin solution in 40 mM phosphate, 25 mM
NaCl, pH 7.0.
SSNMR samples: MLVs were collected by centrifugation (20,000×g) and loaded
into ssNMR rotors. For 3.2 mm rotors, we used 800 nmol of antibiotic with
unlabelled Lipid II or I, while we used 400 nmol with labelled Lipid II. For 1.3 mm
rotors, samples contained 200 nmol of antibiotic for unlabelled Lipid II or I, while
we used 100 nmol for labelled Lipid II. For all ssNMR samples, we used 4 mol
%/mol Lipid II or I in the MLVs.
Native membrane vesicle preparations were obtained from Micrococcus flavus
DSM 179013,16. The amount of antibiotic was ~7.5 and 30 nmol for the 1.3 and 3.2
mm rotors, respectively.
Prior to the DNP measurements, the DNP samples were suspended in 60%
glycerol-d8, 35% buffer solution (25 mM NaCl, 15 mM Tris–HCl pH 7.0 final
concentration), and 5% 15 mM AMUPol (final concentration) in D2O.
Synthesis of [R4L10]-teixobactin. Labelled teixobactins were synthesized using
adapted protocols, described in detail in Supplementary Figs. 15, 16, and 1710. For
simplicity, in this paper D-Arg4-Leu10-teixobactin is represented as [R4L10]-teix-
obactin and Leu10-teixobactin as [L10]-teixobactin.
Steps are illustrated in Supplementary Fig. 15: (step a) 2-Chlorotrityl chloride
resin (manufacturer’s loading= 1.6 mmol/g, 150 mg resin) was swelled in DCM in
a reactor. To this resin was added 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM and
the reactor was shaken for 3 h. The loading determined by UV absorption of the
piperidine-dibenzofulvene adduct was calculated to be 0.56 mmol/g, (150 mg
resin, 0.084 mmol). Any unreacted resin was capped with MeOH:DIPEA:DCM=
1:2:7 by shaking for 1 h. (step b) The Fmoc protecting group was deprotected
using 20% piperdine in DMF by shaking for 3 min, followed by draining and
shaking again with 20% piperidine in DMF for 10 min. AllocHN-D-Thr-OH was
then coupled to the resin by adding 3 eq. of the AA, 3 eq. HATU, and 6 eq. DIPEA
in DMF and shaking for 1.5 h at room temperature. (step c) Esterification was
performed using 10 eq. of Fmoc-Ile-OH, 10 eq. DIC, and 5 mol% DMAP in DCM
and shaking the reaction for 2 h. This was followed by capping the unreacted
alcohol using 10% Ac2O/DIPEA in DMF shaking for 30 min and Fmoc was
removed using protocol described earlier in step (b). (step d) Fmoc-Leu-OH was
coupled using 4 eq. of AA, 4 eq. HATU, and 8 eq. DIPEA in DMF and shaking for
1 h followed by Fmoc deprotection using 20% piperidine in DMF as described
earlier. (step e) The N terminus of Leu was protected using 10 eq. Trt-Cl and 15%
Et3N in DCM and shaking for 1 h. Protection was verified by Ninhydrin colour
test. (step f) The Alloc protecting group of D-Thr was removed using 0.2 eq. [Pd
(PPh3)]0 and 24 eq. PhSiH3 in dry DCM under argon for 20 min. This procedure
was repeated and the resin was washed thoroughly with DCM and DMF to
remove any excess Pd stuck to the resin (step g). All amino acids were coupled
using 4 eq. amino acid, 4 eq. HATU, and 8 eq. DIPEA for 1 h. (step h) The peptide
was cleaved from the resin without cleaving off the protecting groups of the amino
acid sidechains using TFA:TIS:DCM= 2:5:93 and shaking for 1 h. (step i) The
solvent was evaporated and the peptide was dissolved in DMF to which 1 eq.
HATU and 10 eq. DIPEA were added and the reaction was stirred for 30 min to
perform the cyclisation. (step j) The sidechain protecting groups were then cleaved
off using TFA:TIS:H2O= 95:2.5:2.5 by stirring for 1 h. The peptide was
precipitated using cold Et2O (−20 °C) and centrifuging at 7000 rpm to obtain a
white solid. This solid was further purified using RP-HPLC using the protocols
described in Supplementary Fig. 16c, d10. The teixobactin analogues (1–2) were
identified by MS in positive mode (Supplementary Table 4 and Supplementary
Fig. 16e, f).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this manuscript are available from the corresponding
author upon reasonable request. A reporting summary for this Article is available as a
Supplementary Information file. The solid-state NMR assignments of [R4L10]-
teixobactin and Lysine-Lipid II have been deposited in the BMRB (accession number
50202). The coordinates of the [R4L10]-teixobactin–Lipid II complex have been
deposited in the PDB database PDB 6YFY. The source data underlying Figs. 1d, 2e, 4c,
and Supplementary Figs. 2b, 3a–c, 10a, 11b, c are provided as a Source Data file.
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